<DOC>
	<DOC>NCT02581189</DOC>
	<brief_summary>This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free ABBVIE REGIMEN ± RBV in participants with chronic hepatitis C (CHC) in a real life setting across clinical practice patient populations in Canada.</brief_summary>
	<brief_title>Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Confirmed, CHC, genotype 1 or 4, treatmentnaïve or experienced participants receiving combination therapy with the interferonfree ABBVIE REGIMEN ± RBV If RBV is coadministered with the ABBVIE REGIMEN, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy) Participants must voluntarily sign and date a participant authorization to use and/or disclose his/her anonymized health data prior to inclusion into the study Patient participating or intending to participate in a concurrent interventional therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Patient reported outcomes</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Influence of adherence</keyword>
	<keyword>Genotype 1 or 4</keyword>
</DOC>